Related Experiment Videos
Paroxysmal nocturnal hemoglobinuria
1Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Smith7@mskcc.org
Summary
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder causing red blood cell destruction and thrombosis. Diagnosis involves specific lab tests, with stem cell transplant offering a potential cure.
Area of Science:
- Hematology
- Immunology
- Genetics
Background:
- Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disorder.
- It is characterized by intravascular hemolysis, cytopenias, infections, bone marrow hypoplasia, and thrombosis.
- A deficiency in glycosylphosphatidylinositol (GPI)-anchored proteins, like CD55 and CD59, leads to complement-mediated red blood cell lysis.
Purpose of the Study:
- To summarize the key features of Paroxysmal nocturnal hemoglobinuria (PNH).
- To outline the diagnostic approaches for PNH.
- To discuss current and potential curative treatments for PNH.
Main Methods:
- Review of the pathophysiology of PNH.
- Description of clinical presentation and diagnostic laboratory tests.
- Summary of treatment modalities including supportive care and hematopoietic stem cell transplantation.
Main Results:
- PNH results from a somatic mutation affecting hematopoietic stem cells.
- Patients typically present with anemia and hemoglobinuria.
- Diagnostic methods include the sucrose hemolysis test, Ham acid hemolysis test, and fluorescent-activated cell analysis.
Conclusions:
- PNH shares features with aplastic anemia and myelodysplastic syndrome, and can evolve into acute leukemia.
- Supportive treatments include transfusions, anticoagulation, and antibiotics.
- Hematopoietic stem cell transplantation is a potentially curative option for PNH.